Abstract
The effect of the progestogen medroxyprogesterone acetate on metastases from renal, endometrial and other tumours has been studied in 25 patients. Seven patients with renal and endometrial tumours had a useful response, pulmonary metastases and a large primary renal tumour showing the greatest effect. Bony metastases were unaffected by the drug and were treated by local radiotherapy. If a response occurred, it did so within 3 months.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Paine, C., Wright, F. & Ellis, F. The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body. Br J Cancer 24, 277–282 (1970). https://doi.org/10.1038/bjc.1970.31
Issue Date:
DOI: https://doi.org/10.1038/bjc.1970.31